Better Than Latisse » allergan

Allergan begins trials on hair-growth drug

epionebh — Wed, 05 Jan 2011 07:00:00 +0000

Drugmaker Allergan is recruiting volunteers for clinical trials of a hair-growth treatment based on the active ingredient in Latisse (bimatoprost ophthalmic solution, 0.03 percent), the company’s eyelash-growth treatment. (Source: Modern Medicine)

See more here:
Allergan begins trials on hair-growth drug

Latisse gains popularity among those seeking longer, fuller lashes

epionebh — Sun, 01 Aug 2010 05:00:00 +0000

St. Louis — As women become more familiar and comfortable with the idea of a medication that can help give them the kind of lush, long eyelashes they’ve always wanted, physicians have increasingly found themselves prescribing Latisse (bimatoprost ophthalmic solution 0.03 percent, Allergan) and addressing eyelash issues previously dealt with primarily at the cosmetics counter. (Source: Modern Medicine)

Read the rest here:
Latisse gains popularity among those seeking longer, fuller lashes

Glaucoma eye drops drug Latisse used OTC to make long eyelashes but some now face side effects

epionebh — Tue, 13 Jul 2010 19:51:00 +0000

From the NYTimes:Latisse is the same formula as Lumigan, Allerganâ€™s eyedrops for glaucoma, which reduces eye pressure but also happens to grow lashes. Both are also known as bimatoprost ophthalmic solution.

Go here to read the rest:
Glaucoma eye drops drug Latisse used OTC to make long eyelashes but some now face side effects

Latisse Faces Patent Challenge

epionebh — Tue, 13 Jul 2010 07:03:23 +0000

The FDA said a company is challenging Allergan’s patent protection for the eyelash drug Latisse, looking to make a generic version. (Source: WSJ.com: Health)

See original here:
Latisse Faces Patent Challenge

From Serendipity to Pilot Study and Then Pivotal Trial: Bimatoprost Topical for Eyelash Growth

epionebh — Thu, 01 Apr 2010 22:00:00 +0000

Dr. Cohen has been a consultant and clinical trial investigator for Allergan (including related to Latisse).

Read the original:
From Serendipity to Pilot Study and Then Pivotal Trial: Bimatoprost Topical for Eyelash Growth

Policy & Practice

epionebh — Mon, 30 Nov 2009 22:00:00 +0000

Can’t get enough Policy & Practice? Check out our new podcast each Monday

See the rest here:
Policy & Practice

FDA: Allergan’s Web Site Is Misleading

epionebh — Thu, 17 Sep 2009 00:56:01 +0000

The FDA said the Web site of Allergan’s Latisse is misleading because it suggests the company’s eyelash thickener is more safe than proven. (Source: WSJ.com: Health)

Allergan Announces U.S. Food and Drug Administration (FDA) Approval of Latisse — First and Only Treatment Approved by the FDA for Hypotrichosis of…

epionebh — Mon, 29 Dec 2008 16:34:25 +0000

IRVINE, Calif.–(BUSINESS WIRE)–Dec 26, 2008 – Allergan, Inc. today announced the U.S. Food and Drug Administration (FDA) has approved Latisse (bimatoprost ophthalmic solution) 0.03% as a novel treatment for hypotrichosis of the eyelashes.

Allergan Gets Nod For Eyelash Treatment

epionebh — Fri, 26 Dec 2008 22:27:40 +0000

Eye care and cosmetic drug maker Allergan on Friday said its eyelash growth treatment Latisse received Food and Drug Administration approval,… (Source: Investor’s Business Daily: HEALTH)

See the original post here:
Allergan Gets Nod For Eyelash Treatment

FDA Advisory Committee Unanimously Recommends Approval of Latisse (Bimatoprost Solution 0.03%) as a Treatment for Hypotrichosis of Eyelashes

epionebh — Mon, 08 Dec 2008 11:15:58 +0000

IRVINE, Calif.–(BUSINESS WIRE)–Dec 5, 2008 – Allergan, Inc. today announced the U.S. Food and Drug Administration (FDA) Dermatologic and Ophthalmic Drugs Advisory Committee (DODAC) voted unanimously (9-0) to recommend that the FDA approve Latisse…

Original post:
FDA Advisory Committee Unanimously Recommends Approval of Latisse (Bimatoprost Solution 0.03%) as a Treatment for Hypotrichosis of Eyelashes